Table 1 Demographic data, autonomic manifestations and electrodiagnostic data of the studied groups
From: Serum sclerostin and sympathetic skin response: relationship with myeloma bone disease
Smoldering myeloma | Multiple myeloma patients | p+ | Controls | p* | ||
|---|---|---|---|---|---|---|
Group I (N = 35) | Group II (N = 35) | Group III (N = 35) | ||||
Gender (male/female) | 20 (57%)/15 (43%) | 18 (51%)/17 (49%) | 0.6 | 16 (46%)/19 (54%) | 0.36, 0.68 | |
Age: median (range) | 65 (36–85) | 66 (40–75) | 0.3 | 59 (49–73) | 0.21, 0.16 | |
Autonomic manifestations | 8 (23%) | 17 (48%)+ | 0.03 | – | – | |
Undetectable SSR | 6 (17%)* | 15 (42%)*+ | 0.02 | 3 (6%) | 0.01, 0.01 | |
SSR amplitude/µv | UL (median n. stimulation) | 1300 | 500*+ | 0.01 | 2100 | 0.1, 0.02 |
LL (tibial n. stimulation) | 900 | 300*+ | 0.03 | 1600 | 0.4, 0.02 | |